Navigation Links
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

or "Accentia") is a vertically integrated biopharmaceutical company focused on the development and commercialization of drug candidates that are in late-stage clinical development and typically are based on active pharmaceutical ingredients that have been previously approved by the FDA for other indications. Usually these drug candidates can access the accelerated 505(b)(2) regulatory approval pathway, which is generally less time-consuming and less expensive than the typical 505(b)(1) pathway that must be used for new chemical entities. The Company's lead product candidate is SinuNase(TM), a novel application and formulation of a known therapeutic to treat chronic rhinosinusitis. SinuNase has been granted Fast Track status by the FDA and it is currently in a pivotal Phase 3 clinical trial. During this fiscal year, the Company also plans to file an Investigative New Drug (IND) for a pivotal Phase 3 clinical trial of Revimmune, to treat numerous autoimmune diseases with an initial indication targeting refractory relapsing-remitting Multiple Sclerosis. Revimmune is based on pulsed, ultra-high dosing of a well-known chemotherapeutic agent under a risk management program. Additionally, through an investment strategy, the Company has acquired the majority ownership interest in Biovest International, Inc. ("Biovest"), (BVTI.OB) and a royalty interest in Biovest's lead drug candidate, BiovaxID(TM) and any other biologic products developed by Biovest. Biovest is currently conducting a pivotal Phase 3 clinical trial for BiovaxID which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA. In addition to these product candidates, the Company has a specialty pharmaceutical business which markets products focused on respiratory disease and an analytical consulting business that serves customers in the biopharmaceutical industry. For further information, visit the Company W
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
Post Your Comments:
(Date:2/27/2015)... YORK , Feb. 27, 2015 Securities ... the board of Salix Pharmaceuticals, Ltd. (NASDAQ: ... $158.00 per share. Concerned SLXP investors are encouraged to ... The investigation focuses upon the shareholder ... agreement, Salix shareholders would receive only $158.00 per share ...
(Date:2/27/2015)... HOUSTON, TX , Feb. 27, 2015 /PRNewswire/ - ESSA ... Bloom Burton & Co. Ltd. ("Bloom Burton") today announced ... "Lock-Up") 2,353,130 common shares of the Company ("Common Shares") ... the Lock-Up. Of the Common Shares released from the ... release from the Lock-Up while the remainder will be ...
(Date:2/27/2015)... MARLBOROUGH, Mass. , Feb. 27, 2015  Boston ... to participate in the Barclays 2015 Annual Healthcare Conference ... . Dan Brennan , executive vice ... , vice president, Investor Relations, will participate in a ... the host analyst at approximately 1:05 p.m. ET. Following ...
Breaking Medicine Technology:ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2
... 2011 Misonix, Inc. (NASDAQ: MSON ... and markets innovative therapeutic ultrasonic products worldwide for ... surgery and other surgical and medical applications, announced ... Symposium on Advances in Skin and Wound Care ...
... Every year thousands of children are hospitalized — and ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Teens share stolen prescription ... pills that look like candy. In this ... can prevent harm by locking your medicine up. ...
Cached Medicine Technology:Misonix Exhibits at 26th Annual Clinical Symposium on Advances in Skin and Wound Care 2Misonix Exhibits at 26th Annual Clinical Symposium on Advances in Skin and Wound Care 3
(Date:2/27/2015)... NY (PRWEB) February 27, 2015 In ... to the community by providing free dental care from ... has partnered with Dentistry from the Heart, and ... 11, 2015. The first 50 patients who are in ... they can’t afford, will have access to high­quality service ...
(Date:2/27/2015)... 2015 The federal court overseeing more ... use of the statin medication can increase a person’s ... new order pertaining discovery in the cases selected for ... comments. The Order, which was issued in the U.S. ... directs the parties to schedule certain witness depositions before ...
(Date:2/27/2015)... According to court documents, Donna Pirolli was ... 2013 and underwent a procedure during which a duodenoscope ... Because the duodenoscope allegedly had not been properly cleaned, ... Enterobacteriaceae (CRE). , A lawsuit has been ... behalf of Ms. Pirolli alleging that Lutheran General Hospital ...
(Date:2/27/2015)... Adding to its rich history ... Advertising & Marketing has added Sedation Systems of ... patented NITROUSEAL® N20 closed mask and breathing circuit ... , Sedation Systems, http://www.sedationsystems.com is dedicated ... level, though it focuses primarily on pediatric patients. ...
(Date:2/27/2015)... Greene Hospice, a 10-bed facility located on the 15th floor ... Side, was officially dedicated and blessed at a ceremony by ... Dolan. , Thomas J. Fahey, Jr., MD, chairman of the ... ArchCare Board of Trustees, presided over the event with remarks ... and Christina McInerney, president and CEO of The Jerome L. ...
Breaking Medicine News(10 mins):Health News:Dr. Umanoff Unites with Dentistry from the Heart to Provide Community with Charitable Dental Care 2Health News:Dr. Umanoff Unites with Dentistry from the Heart to Provide Community with Charitable Dental Care 3Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 2Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 3Health News:Lawsuit Alleges Blame on Scope Manufacturer for "Superbug" Outbreak 2Health News:Benedict Advertising & Marketing Signs Sedation Systems 2Health News:The Dawn Greene Hospice Is Officially Dedicated 2Health News:The Dawn Greene Hospice Is Officially Dedicated 3
... ultrasound and specially modified contrast agents may allow researchers ... to research published in the March issue of The ... The technique enables researchers to visualize tumor activity at ... be helpful for the early detection of disease," said ...
... If the behavior of the seasonal form of the ... are good that most strains of the pandemic H1N1 flu ... for use against it. Researchers at Ohio State University ... virus, which first infected humans during the 1918 pandemic. It ...
... ... beef sold at checkout could help save lives when E. coli outbreaks happen because ... identify the products that are making people sick in order to bring outbreaks under ... ...
... ... has launched an improved web viewer for its flagship Evercore® – Clinical Enterprise Suite ... of the size of the facility. , ... Milwaukee, WI (PRWEB) March 1, 2010 -- TeraMedica Healthcare Technology, ...
... ... in Pharma, Health and Wellness. , ... Philadelphia, PA (PRWEB) March 1, 2010 -- Acknowledging more than 13 ... for specialization, Razorfish has launched Razorfish Health , a dedicated health and wellness ...
... ... ... ... ...
Cached Medicine News:Health News:The proof's in the bubbles 2Health News:Pandemic flu, like seasonal H1N1, shows signs of resisting Tamiflu 2Health News:Pandemic flu, like seasonal H1N1, shows signs of resisting Tamiflu 3Health News:Pandemic flu, like seasonal H1N1, shows signs of resisting Tamiflu 4Health News:Food Safety Attorney Fred Pritzker Calls on Food Retailers to Keep Precise Beef Handling Records 2Health News:Food Safety Attorney Fred Pritzker Calls on Food Retailers to Keep Precise Beef Handling Records 3Health News:TeraMedica Unveils Improved Univision, Now Offering a Multi-Layer Enterprise Viewing Platform 2Health News:Razorfish Launches Independent Dedicated Health Brand 2Health News:Razorfish Launches Independent Dedicated Health Brand 3Health News:Razorfish Launches Independent Dedicated Health Brand 4Health News:California to Examine Health Impacts of Landmark Cap-and-Trade Program 2Health News:California to Examine Health Impacts of Landmark Cap-and-Trade Program 3Health News:California to Examine Health Impacts of Landmark Cap-and-Trade Program 4Health News:California to Examine Health Impacts of Landmark Cap-and-Trade Program 5
... fast, single-solution staining, Hema-Quik II ... slides into stain solution for ... to deionized water for five ... second time by dipping quickly ...
Used in stat or routine procedures utilizing the dip or rack method of staining blood smears or as a counter-stain in reticulocyte counting. Comes as a part of a kit (8 oz each), or in 16 oz, 32 oz a...
... Our Buffered Wright-Giemsa Stain is ... contains the fixative, buffer, and ... staining of blood smears. It ... bottle for ease of use ...
Our Wright stain is a dual-use stain for peripheral blood and bone marrow smears. It produces results similar to those of the Giemsa stain with a slightly greater contrast....
Medicine Products: